Results 11 to 20 of about 5,866 (194)

Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety

BMC Cancer, 2021
Background Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), is commonly used to prevent febrile neutropenia (FN), a potentially life-threatening complication, following myelosuppressive chemotherapy.
Reshma Mahtani, Jeffrey Crawford, Sinéad M. Flannery, Tatiana Lawrence, Jennifer Schenfeld, Prasad L. Gawade   +5 more
doaj   +1 more source

Comparison of Efficacy and Safety of Lupin’s Pegfilgrastim with Neulastim® as an Adjunct to Chemotherapy in Patients with Non Myeloid Malignancies: A Randomised Phase III Clinical Study [PDF]

Journal of Clinical and Diagnostic Research, 2022
Introduction: Pegfilgrastim is indicated in patients receiving myelosuppressive anticancer drugs to reduce the Duration of Severe Neutropenia (DSN) and incidence of Febrile Neutropenia (FN).
Minish Jain, Sharad Desai, Rajnish Nagarkar, Rakesh Neve, Unmesh Takalkar, Dhananjay Bakhle, Chirag Shah   +6 more
doaj   +1 more source

A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis

EClinicalMedicine, 2022
Summary: Background: In trials conducted in India, recombinant granulocyte colony stimulating factor (GCSF) improved survival in alcohol-associated hepatitis (AH).
John A. Tayek, Andrew A. Stolz, Danh V. Nguyen, M. Wayne Fleischman, John A. Donovan, Joseph M. Alcorn, Daniel C-K. Chao, Aliya Asghar, Timothy R. Morgan, Divya Birudaraju, Greg Botwin, Hema Buddha, Lavanya Cherukuri, Sheena Cruz, Monique French, Rachel Gonzalez, Jessica Gozum, Rebecca Gutierrez, Sajad Hamal, Preston Head, Carol Jones, Neil Kaplowitz, Robert Lee, Lauren MacHarg, Susan Milstein, Yuxin Ouyang, Christy Rico, Cory Zarick   +27 more
doaj   +1 more source

Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage

Cancer Treatment and Research Communications, 2021
Evidence-based US guidelines provide recommendations for the use of granulocyte colony-stimulating factor (G-CSF) as supportive therapy in patients with cancer receiving chemotherapy.
Jeffrey Crawford, Donald C. Moore, Vicki A. Morrison, David Dale   +3 more
doaj   +1 more source

Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: a systematic review and meta-analysis

Hematology, 2023
Objectives There is no meta-analysis about the effects of pegfilgrastim on the occurrence of febrile neutropenia (FN) in pediatric/adolescent cancer patients.
Xia Zhu, Weiling Zhang, Yi Zhang, Yizhuo Wang, Huimin Hu, Jing Li, Yan Zhou, Tao Han, Dongsheng Huang   +8 more
doaj   +1 more source

Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience

Journal of Pharmaceutical Health Care and Sciences, 2023
Background Pegfilgrastim is widely used for the prevention of febrile neutropenia (FN) in patients receiving myelosuppressive chemotherapy for various types of cancer.
Shinya Tsuboi, Tatsuya Hayama, Katsuhiro Miura, Akihiro Uchiike, Daisuke Tsutsumi, Takashi Yamauchi, Yoshihiro Hatta, Susumu Ootsuka   +7 more
doaj   +1 more source

Primary prophylaxis of neutropenia in women affected by breast cancer undergoing adjuvant chemotherapy with fec 100+/- docetaxel. Comparison of efficacy and tolerability between lenograstim and pegfilgrastim [PDF]

, 2015
Objectives: evaluate safety and toxicity of a single injection of pegfilgrastim compared to daily administration of lenograstim in breast cancer patient undergoing adjuvant ...
Caruso, Davide, Congedi, Fp, Giannarelli, D, Giordani, Erika, Papa, Anselmo, Ricci, Fabio, Rossi, Luigi Enrico, Tomao, Federica, Verrico, Monica, Zaccarelli, Eleonora   +9 more
core   +1 more source

Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy

Experimental Hematology & Oncology, 2018
Background Chemotherapy-induced neutropenia is a common result of myelosuppressive chemotherapy treatment. Infections such as febrile neutropenia (FN) are sensitive to the duration of neutropenia as well as the depth of absolute neutrophil count (ANC) at
Kalpna Desai, Priya Misra, Sanyukta Kher, Nirmesh Shah   +3 more
doaj   +1 more source

Drug-induced aortitis of the subclavian artery caused by pegfilgrastim: a case report

Surgical Case Reports, 2021
Background Pegfilgrastim is a modified version of granulocyte-colony stimulating factor (G-CSF), with a polyethylene glycol (PEG) that prolongs its half-life in peripheral blood.
Hikari Jimbo, Yoshiya Horimoto, Misato Okazaki, Yumiko Ishizuka, Hidenori Kido, Mitsue Saito   +5 more
doaj   +1 more source

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma [PDF]

, 2010
Background: The use of chemotherapy regimens with moderate or high risk of febrile neutropenia (defined as having a FN incidence of 10% or more) and the respective incidence and clinical management of FN in breast cancer and NHL has not been studied in ...
Gerlier, Laetitia, Lamotte, Mark, Awada, Ahmad, Bosly, André, Bries, Greet, Cocquyt, Veronique, Focan, Christian, Henry, Stephanie, Lalami, Yassine, Machiels, Jean-Pascal, Mebis, Jeroen, Straetmans, Nicole, Verhoeven, Didier, Somers, Luc   +13 more
core   +2 more sources